July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Manufacturing of novel ultra-high molecular weight branched biopolymers for use with antibody based bioconjugate therapies
Author Affiliations & Notes
  • Stephen Raillard
    Kodiak Sciences, Palo Alto, California, United States
  • Didier G Benoit
    Kodiak Sciences, Palo Alto, California, United States
  • Wayne To
    Kodiak Sciences, Palo Alto, California, United States
  • Yuhua Hu
    Kodiak Sciences, Palo Alto, California, United States
  • Stephen Charles
    Kodiak Sciences, Palo Alto, California, United States
  • D. Victor Perlroth
    Kodiak Sciences, Palo Alto, California, United States
  • Footnotes
    Commercial Relationships   Stephen Raillard, None; Didier Benoit, None; Wayne To, None; Yuhua Hu, None; Stephen Charles, None; D. Victor Perlroth, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5311. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stephen Raillard, Didier G Benoit, Wayne To, Yuhua Hu, Stephen Charles, D. Victor Perlroth; Manufacturing of novel ultra-high molecular weight branched biopolymers for use with antibody based bioconjugate therapies. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5311.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Development of an aqueous, optically clear biocompatible polymer platform that can pair with therapeutic antibodies to generate next generation therapies with enhanced durability and stability as compared to current agents.

Methods : We designed a multi-branched polymerization initiator and studied polymerizations with methacrylate-based phosphorylcholine containing monomers with the goal of producing very large (>2,000 monomers) water-soluble polymers with controlled molecular weight, polydispersity, composition, chain architecture, and site-specific functionality. The desired antibodies of choice can be attached to the biopolymer via a stable covalent linkage. Key success factors were the parallel optimization of initiator architecture, monomer features and the fine-tuning of controlled/living polymerization chemical process parameters.

Results : A manufacturing process was developed and successfully applied in the production of a well characterized custom biopolymer under current good manufacturing practices on batch scales approaching 10 kilograms. This is sufficient manufacturing scale to support clinical development through early commercialization of Kodiak’s ophthalmic biologics pipeline.

Conclusions : A novel biopolymer platform was developed that features a high molecular weight phosphorylcholine based biopolymer that is manufactured with high-fidelity and allows for the development of well-characterized, optically clear antibody based bioconjugate therapies.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×